

Global Neurotransmitter Endogenous Regulation Platform Market 2025 by Company, Regions, Type and Application, Forecast to 2031

<https://marketpublishers.com/r/G7BC650C86FEEN.html>

Date: September 2025

Pages: 102

Price: US\$ 3,480.00 (Single User License)

ID: G7BC650C86FEEN

Abstracts

According to our (Global Info Research) latest study, the global Neurotransmitter Endogenous Regulation Platform market size was valued at US\$ 1339 million in 2024 and is forecast to a readjusted size of USD 2961 million by 2031 with a CAGR of 12.0% during review period.

The neurotransmitter endogenous regulation platform is a system built on neuroscience and molecular biotechnology, which is used to regulate the synthesis, release, reuptake and metabolism of neurotransmitters in the body, thereby maintaining the functional balance of the nervous system. This platform usually combines technologies such as gene editing, small molecule intervention or targeted vectors to accurately regulate the endogenous levels of key neurotransmitters such as dopamine, glutamate, and 5-hydroxytryptamine, and is widely used in the study of the mechanisms of neuropsychiatric diseases and the development of individualized intervention strategies.

This report is a detailed and comprehensive analysis for global Neurotransmitter Endogenous Regulation Platform market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Neurotransmitter Endogenous Regulation Platform market size and forecasts, in

consumption value (\$ Million), 2020-2031

Global Neurotransmitter Endogenous Regulation Platform market size and forecasts by region and country, in consumption value (\$ Million), 2020-2031

Global Neurotransmitter Endogenous Regulation Platform market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2020-2031

Global Neurotransmitter Endogenous Regulation Platform market shares of main players, in revenue (\$ Million), 2020-2025

The Primary Objectives in This Report Are:

- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Neurotransmitter Endogenous Regulation Platform
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace

This report profiles key players in the global Neurotransmitter Endogenous Regulation Platform market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Neurocrine Biosciences, Intra-Cellular Therapies, BrainsWay, BlackThorn Therapeutics, MindMed, Voyager Therapeutics, COMPASS Pathways, Neuroelectronics, Cervel Therapeutics, Axsome Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Neurotransmitter Endogenous Regulation Platform market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Chemical Molecular Regulation Platform

Bioengineering Regulation Platform

Market segment by Application

Hospital

Clinic

Others

Market segment by players, this report covers

Neurocrine Biosciences

Intra-Cellular Therapies

BrainsWay

BlackThorn Therapeutics

MindMed

Voyager Therapeutics

COMPASS Pathways

Neuroelectronics

Cervel Therapeutics

Axsome Therapeutics

Atai Life Sciences

Neumora Therapeutics

Alto Neuroscience

An Ranfei

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Neurotransmitter Endogenous Regulation Platform product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Neurotransmitter Endogenous Regulation Platform, with revenue, gross margin, and global market share of Neurotransmitter Endogenous Regulation Platform from 2020 to 2025.

Chapter 3, the Neurotransmitter Endogenous Regulation Platform competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025. and Neurotransmitter Endogenous Regulation Platform market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Neurotransmitter Endogenous Regulation Platform.

Chapter 13, to describe Neurotransmitter Endogenous Regulation Platform research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Neurotransmitter Endogenous Regulation Platform by Type

1.3.1 Overview: Global Neurotransmitter Endogenous Regulation Platform Market Size by Type: 2020 Versus 2024 Versus 2031

1.3.2 Global Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Type in 2024

1.3.3 Chemical Molecular Regulation Platform

1.3.4 Bioengineering Regulation Platform

1.4 Global Neurotransmitter Endogenous Regulation Platform Market by Application

1.4.1 Overview: Global Neurotransmitter Endogenous Regulation Platform Market Size by Application: 2020 Versus 2024 Versus 2031

1.4.2 Hospital

1.4.3 Clinic

1.4.4 Others

1.5 Global Neurotransmitter Endogenous Regulation Platform Market Size & Forecast

1.6 Global Neurotransmitter Endogenous Regulation Platform Market Size and Forecast by Region

1.6.1 Global Neurotransmitter Endogenous Regulation Platform Market Size by Region: 2020 VS 2024 VS 2031

1.6.2 Global Neurotransmitter Endogenous Regulation Platform Market Size by Region, (2020-2031)

1.6.3 North America Neurotransmitter Endogenous Regulation Platform Market Size and Prospect (2020-2031)

1.6.4 Europe Neurotransmitter Endogenous Regulation Platform Market Size and Prospect (2020-2031)

1.6.5 Asia-Pacific Neurotransmitter Endogenous Regulation Platform Market Size and Prospect (2020-2031)

1.6.6 South America Neurotransmitter Endogenous Regulation Platform Market Size and Prospect (2020-2031)

1.6.7 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size and Prospect (2020-2031)

2 COMPANY PROFILES

2.1 Neurocrine Biosciences

2.1.1 Neurocrine Biosciences Details

2.1.2 Neurocrine Biosciences Major Business

2.1.3 Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Product and Solutions

2.1.4 Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)

2.1.5 Neurocrine Biosciences Recent Developments and Future Plans

2.2 Intra-Cellular Therapies

2.2.1 Intra-Cellular Therapies Details

2.2.2 Intra-Cellular Therapies Major Business

2.2.3 Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Product and Solutions

2.2.4 Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)

2.2.5 Intra-Cellular Therapies Recent Developments and Future Plans

2.3 BrainsWay

2.3.1 BrainsWay Details

2.3.2 BrainsWay Major Business

2.3.3 BrainsWay Neurotransmitter Endogenous Regulation Platform Product and Solutions

2.3.4 BrainsWay Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)

2.3.5 BrainsWay Recent Developments and Future Plans

2.4 BlackThorn Therapeutics

2.4.1 BlackThorn Therapeutics Details

2.4.2 BlackThorn Therapeutics Major Business

2.4.3 BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions

2.4.4 BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)

2.4.5 BlackThorn Therapeutics Recent Developments and Future Plans

2.5 MindMed

2.5.1 MindMed Details

2.5.2 MindMed Major Business

2.5.3 MindMed Neurotransmitter Endogenous Regulation Platform Product and Solutions

2.5.4 MindMed Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)

- 2.5.5 MindMed Recent Developments and Future Plans
- 2.6 Voyager Therapeutics
 - 2.6.1 Voyager Therapeutics Details
 - 2.6.2 Voyager Therapeutics Major Business
 - 2.6.3 Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions
 - 2.6.4 Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
 - 2.6.5 Voyager Therapeutics Recent Developments and Future Plans
- 2.7 COMPASS Pathways
 - 2.7.1 COMPASS Pathways Details
 - 2.7.2 COMPASS Pathways Major Business
 - 2.7.3 COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Product and Solutions
 - 2.7.4 COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
 - 2.7.5 COMPASS Pathways Recent Developments and Future Plans
- 2.8 Neuroelectrics
 - 2.8.1 Neuroelectrics Details
 - 2.8.2 Neuroelectrics Major Business
 - 2.8.3 Neuroelectrics Neurotransmitter Endogenous Regulation Platform Product and Solutions
 - 2.8.4 Neuroelectrics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
 - 2.8.5 Neuroelectrics Recent Developments and Future Plans
- 2.9 Cervel Therapeutics
 - 2.9.1 Cervel Therapeutics Details
 - 2.9.2 Cervel Therapeutics Major Business
 - 2.9.3 Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions
 - 2.9.4 Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
 - 2.9.5 Cervel Therapeutics Recent Developments and Future Plans
- 2.10 Axsome Therapeutics
 - 2.10.1 Axsome Therapeutics Details
 - 2.10.2 Axsome Therapeutics Major Business
 - 2.10.3 Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions
 - 2.10.4 Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform

Revenue, Gross Margin and Market Share (2020-2025)

2.10.5 Axsome Therapeutics Recent Developments and Future Plans

2.11 Atai Life Sciences

2.11.1 Atai Life Sciences Details

2.11.2 Atai Life Sciences Major Business

2.11.3 Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Product and Solutions

2.11.4 Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)

2.11.5 Atai Life Sciences Recent Developments and Future Plans

2.12 Neumora Therapeutics

2.12.1 Neumora Therapeutics Details

2.12.2 Neumora Therapeutics Major Business

2.12.3 Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions

2.12.4 Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)

2.12.5 Neumora Therapeutics Recent Developments and Future Plans

2.13 Alto Neuroscience

2.13.1 Alto Neuroscience Details

2.13.2 Alto Neuroscience Major Business

2.13.3 Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Product and Solutions

2.13.4 Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)

2.13.5 Alto Neuroscience Recent Developments and Future Plans

2.14 An Ranfei

2.14.1 An Ranfei Details

2.14.2 An Ranfei Major Business

2.14.3 An Ranfei Neurotransmitter Endogenous Regulation Platform Product and Solutions

2.14.4 An Ranfei Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)

2.14.5 An Ranfei Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Neurotransmitter Endogenous Regulation Platform Revenue and Share by Players (2020-2025)

3.2 Market Share Analysis (2024)

3.2.1 Market Share of Neurotransmitter Endogenous Regulation Platform by Company Revenue

3.2.2 Top 3 Neurotransmitter Endogenous Regulation Platform Players Market Share in 2024

3.2.3 Top 6 Neurotransmitter Endogenous Regulation Platform Players Market Share in 2024

3.3 Neurotransmitter Endogenous Regulation Platform Market: Overall Company Footprint Analysis

3.3.1 Neurotransmitter Endogenous Regulation Platform Market: Region Footprint

3.3.2 Neurotransmitter Endogenous Regulation Platform Market: Company Product Type Footprint

3.3.3 Neurotransmitter Endogenous Regulation Platform Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Neurotransmitter Endogenous Regulation Platform Consumption Value and Market Share by Type (2020-2025)

4.2 Global Neurotransmitter Endogenous Regulation Platform Market Forecast by Type (2026-2031)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Application (2020-2025)

5.2 Global Neurotransmitter Endogenous Regulation Platform Market Forecast by Application (2026-2031)

6 NORTH AMERICA

6.1 North America Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2031)

6.2 North America Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2031)

6.3 North America Neurotransmitter Endogenous Regulation Platform Market Size by Country

6.3.1 North America Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2020-2031)

6.3.2 United States Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

6.3.3 Canada Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

6.3.4 Mexico Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

7 EUROPE

7.1 Europe Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2031)

7.2 Europe Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2031)

7.3 Europe Neurotransmitter Endogenous Regulation Platform Market Size by Country

7.3.1 Europe Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2020-2031)

7.3.2 Germany Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

7.3.3 France Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

7.3.4 United Kingdom Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

7.3.5 Russia Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

7.3.6 Italy Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

8 ASIA-PACIFIC

8.1 Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2031)

8.2 Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2031)

8.3 Asia-Pacific Neurotransmitter Endogenous Regulation Platform Market Size by Region

8.3.1 Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value by Region (2020-2031)

8.3.2 China Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

8.3.3 Japan Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

8.3.4 South Korea Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

8.3.5 India Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

8.3.6 Southeast Asia Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

8.3.7 Australia Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

9 SOUTH AMERICA

9.1 South America Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2031)

9.2 South America Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2031)

9.3 South America Neurotransmitter Endogenous Regulation Platform Market Size by Country

9.3.1 South America Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2020-2031)

9.3.2 Brazil Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

9.3.3 Argentina Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2031)

10.2 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2031)

10.3 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size by Country

10.3.1 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2020-2031)

10.3.2 Turkey Neurotransmitter Endogenous Regulation Platform Market Size and

Forecast (2020-2031)

10.3.3 Saudi Arabia Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

10.3.4 UAE Neurotransmitter Endogenous Regulation Platform Market Size and Forecast (2020-2031)

11 MARKET DYNAMICS

11.1 Neurotransmitter Endogenous Regulation Platform Market Drivers

11.2 Neurotransmitter Endogenous Regulation Platform Market Restraints

11.3 Neurotransmitter Endogenous Regulation Platform Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Neurotransmitter Endogenous Regulation Platform Industry Chain

12.2 Neurotransmitter Endogenous Regulation Platform Upstream Analysis

12.3 Neurotransmitter Endogenous Regulation Platform Midstream Analysis

12.4 Neurotransmitter Endogenous Regulation Platform Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Global Neurotransmitter Endogenous Regulation Platform Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
- Table 2. Global Neurotransmitter Endogenous Regulation Platform Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
- Table 3. Global Neurotransmitter Endogenous Regulation Platform Consumption Value by Region (2020-2025) & (USD Million)
- Table 4. Global Neurotransmitter Endogenous Regulation Platform Consumption Value by Region (2026-2031) & (USD Million)
- Table 5. Neurocrine Biosciences Company Information, Head Office, and Major Competitors
- Table 6. Neurocrine Biosciences Major Business
- Table 7. Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Product and Solutions
- Table 8. Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)
- Table 9. Neurocrine Biosciences Recent Developments and Future Plans
- Table 10. Intra-Cellular Therapies Company Information, Head Office, and Major Competitors
- Table 11. Intra-Cellular Therapies Major Business
- Table 12. Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Product and Solutions
- Table 13. Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)
- Table 14. Intra-Cellular Therapies Recent Developments and Future Plans
- Table 15. BrainsWay Company Information, Head Office, and Major Competitors
- Table 16. BrainsWay Major Business
- Table 17. BrainsWay Neurotransmitter Endogenous Regulation Platform Product and Solutions
- Table 18. BrainsWay Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)
- Table 19. BlackThorn Therapeutics Company Information, Head Office, and Major Competitors
- Table 20. BlackThorn Therapeutics Major Business
- Table 21. BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 22. BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 23. BlackThorn Therapeutics Recent Developments and Future Plans

Table 24. MindMed Company Information, Head Office, and Major Competitors

Table 25. MindMed Major Business

Table 26. MindMed Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 27. MindMed Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 28. MindMed Recent Developments and Future Plans

Table 29. Voyager Therapeutics Company Information, Head Office, and Major Competitors

Table 30. Voyager Therapeutics Major Business

Table 31. Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 32. Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 33. Voyager Therapeutics Recent Developments and Future Plans

Table 34. COMPASS Pathways Company Information, Head Office, and Major Competitors

Table 35. COMPASS Pathways Major Business

Table 36. COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 37. COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 38. COMPASS Pathways Recent Developments and Future Plans

Table 39. Neuroelectrics Company Information, Head Office, and Major Competitors

Table 40. Neuroelectrics Major Business

Table 41. Neuroelectrics Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 42. Neuroelectrics Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 43. Neuroelectrics Recent Developments and Future Plans

Table 44. Cervel Therapeutics Company Information, Head Office, and Major Competitors

Table 45. Cervel Therapeutics Major Business

Table 46. Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 47. Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform

Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 48. Cervel Therapeutics Recent Developments and Future Plans

Table 49. Axsome Therapeutics Company Information, Head Office, and Major Competitors

Table 50. Axsome Therapeutics Major Business

Table 51. Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 52. Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 53. Axsome Therapeutics Recent Developments and Future Plans

Table 54. Atai Life Sciences Company Information, Head Office, and Major Competitors

Table 55. Atai Life Sciences Major Business

Table 56. Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 57. Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 58. Atai Life Sciences Recent Developments and Future Plans

Table 59. Neumora Therapeutics Company Information, Head Office, and Major Competitors

Table 60. Neumora Therapeutics Major Business

Table 61. Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 62. Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 63. Neumora Therapeutics Recent Developments and Future Plans

Table 64. Alto Neuroscience Company Information, Head Office, and Major Competitors

Table 65. Alto Neuroscience Major Business

Table 66. Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 67. Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 68. Alto Neuroscience Recent Developments and Future Plans

Table 69. An Ranfei Company Information, Head Office, and Major Competitors

Table 70. An Ranfei Major Business

Table 71. An Ranfei Neurotransmitter Endogenous Regulation Platform Product and Solutions

Table 72. An Ranfei Neurotransmitter Endogenous Regulation Platform Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 73. An Ranfei Recent Developments and Future Plans

Table 74. Global Neurotransmitter Endogenous Regulation Platform Revenue (USD Million) by Players (2020-2025)

Table 75. Global Neurotransmitter Endogenous Regulation Platform Revenue Share by Players (2020-2025)

Table 76. Breakdown of Neurotransmitter Endogenous Regulation Platform by Company Type (Tier 1, Tier 2, and Tier 3)

Table 77. Market Position of Players in Neurotransmitter Endogenous Regulation Platform, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024

Table 78. Head Office of Key Neurotransmitter Endogenous Regulation Platform Players

Table 79. Neurotransmitter Endogenous Regulation Platform Market: Company Product Type Footprint

Table 80. Neurotransmitter Endogenous Regulation Platform Market: Company Product Application Footprint

Table 81. Neurotransmitter Endogenous Regulation Platform New Market Entrants and Barriers to Market Entry

Table 82. Neurotransmitter Endogenous Regulation Platform Mergers, Acquisition, Agreements, and Collaborations

Table 83. Global Neurotransmitter Endogenous Regulation Platform Consumption Value (USD Million) by Type (2020-2025)

Table 84. Global Neurotransmitter Endogenous Regulation Platform Consumption Value Share by Type (2020-2025)

Table 85. Global Neurotransmitter Endogenous Regulation Platform Consumption Value Forecast by Type (2026-2031)

Table 86. Global Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2025)

Table 87. Global Neurotransmitter Endogenous Regulation Platform Consumption Value Forecast by Application (2026-2031)

Table 88. North America Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2025) & (USD Million)

Table 89. North America Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2026-2031) & (USD Million)

Table 90. North America Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2025) & (USD Million)

Table 91. North America Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2026-2031) & (USD Million)

Table 92. North America Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2020-2025) & (USD Million)

Table 93. North America Neurotransmitter Endogenous Regulation Platform

Consumption Value by Country (2026-2031) & (USD Million)

Table 94. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2025) & (USD Million)

Table 95. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2026-2031) & (USD Million)

Table 96. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2025) & (USD Million)

Table 97. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2026-2031) & (USD Million)

Table 98. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2020-2025) & (USD Million)

Table 99. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2026-2031) & (USD Million)

Table 100. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2025) & (USD Million)

Table 101. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2026-2031) & (USD Million)

Table 102. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2025) & (USD Million)

Table 103. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2026-2031) & (USD Million)

Table 104. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value by Region (2020-2025) & (USD Million)

Table 105. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value by Region (2026-2031) & (USD Million)

Table 106. South America Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2025) & (USD Million)

Table 107. South America Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2026-2031) & (USD Million)

Table 108. South America Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2025) & (USD Million)

Table 109. South America Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2026-2031) & (USD Million)

Table 110. South America Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2020-2025) & (USD Million)

Table 111. South America Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2026-2031) & (USD Million)

Table 112. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2020-2025) & (USD Million)

Table 113. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value by Type (2026-2031) & (USD Million)

Table 114. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2020-2025) & (USD Million)

Table 115. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value by Application (2026-2031) & (USD Million)

Table 116. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2020-2025) & (USD Million)

Table 117. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value by Country (2026-2031) & (USD Million)

Table 118. Global Key Players of Neurotransmitter Endogenous Regulation Platform Upstream (Raw Materials)

Table 119. Global Neurotransmitter Endogenous Regulation Platform Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Neurotransmitter Endogenous Regulation Platform Picture
- Figure 2. Global Neurotransmitter Endogenous Regulation Platform Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
- Figure 3. Global Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Type in 2024
- Figure 4. Chemical Molecular Regulation Platform
- Figure 5. Bioengineering Regulation Platform
- Figure 6. Global Neurotransmitter Endogenous Regulation Platform Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
- Figure 7. Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Application in 2024
- Figure 8. Hospital Picture
- Figure 9. Clinic Picture
- Figure 10. Others Picture
- Figure 11. Global Neurotransmitter Endogenous Regulation Platform Consumption Value, (USD Million): 2020 & 2024 & 2031
- Figure 12. Global Neurotransmitter Endogenous Regulation Platform Consumption Value and Forecast (2020-2031) & (USD Million)
- Figure 13. Global Market Neurotransmitter Endogenous Regulation Platform Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
- Figure 14. Global Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Region (2020-2031)
- Figure 15. Global Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Region in 2024
- Figure 16. North America Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)
- Figure 17. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)
- Figure 18. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)
- Figure 19. South America Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)
- Figure 20. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)
- Figure 21. Company Three Recent Developments and Future Plans

Figure 22. Global Neurotransmitter Endogenous Regulation Platform Revenue Share by Players in 2024

Figure 23. Neurotransmitter Endogenous Regulation Platform Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024

Figure 24. Market Share of Neurotransmitter Endogenous Regulation Platform by Player Revenue in 2024

Figure 25. Top 3 Neurotransmitter Endogenous Regulation Platform Players Market Share in 2024

Figure 26. Top 6 Neurotransmitter Endogenous Regulation Platform Players Market Share in 2024

Figure 27. Global Neurotransmitter Endogenous Regulation Platform Consumption Value Share by Type (2020-2025)

Figure 28. Global Neurotransmitter Endogenous Regulation Platform Market Share Forecast by Type (2026-2031)

Figure 29. Global Neurotransmitter Endogenous Regulation Platform Consumption Value Share by Application (2020-2025)

Figure 30. Global Neurotransmitter Endogenous Regulation Platform Market Share Forecast by Application (2026-2031)

Figure 31. North America Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Type (2020-2031)

Figure 32. North America Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Application (2020-2031)

Figure 33. North America Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Country (2020-2031)

Figure 34. United States Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 35. Canada Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 36. Mexico Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 37. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Type (2020-2031)

Figure 38. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Application (2020-2031)

Figure 39. Europe Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Country (2020-2031)

Figure 40. Germany Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 41. France Neurotransmitter Endogenous Regulation Platform Consumption

Value (2020-2031) & (USD Million)

Figure 42. United Kingdom Neurotransmitter Endogenous Regulation Platform

Consumption Value (2020-2031) & (USD Million)

Figure 43. Russia Neurotransmitter Endogenous Regulation Platform Consumption

Value (2020-2031) & (USD Million)

Figure 44. Italy Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 45. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Type (2020-2031)

Figure 46. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Application (2020-2031)

Figure 47. Asia-Pacific Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Region (2020-2031)

Figure 48. China Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 49. Japan Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 50. South Korea Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 51. India Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 52. Southeast Asia Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 53. Australia Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 54. South America Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Type (2020-2031)

Figure 55. South America Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Application (2020-2031)

Figure 56. South America Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Country (2020-2031)

Figure 57. Brazil Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 58. Argentina Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 59. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Type (2020-2031)

Figure 60. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Application (2020-2031)

Figure 61. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Consumption Value Market Share by Country (2020-2031)

Figure 62. Turkey Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 63. Saudi Arabia Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 64. UAE Neurotransmitter Endogenous Regulation Platform Consumption Value (2020-2031) & (USD Million)

Figure 65. Neurotransmitter Endogenous Regulation Platform Market Drivers

Figure 66. Neurotransmitter Endogenous Regulation Platform Market Restraints

Figure 67. Neurotransmitter Endogenous Regulation Platform Market Trends

Figure 68. Porters Five Forces Analysis

Figure 69. Neurotransmitter Endogenous Regulation Platform Industrial Chain

Figure 70. Methodology

Figure 71. Research Process and Data Source

I would like to order

Product name: Global Neurotransmitter Endogenous Regulation Platform Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Product link: <https://marketpublishers.com/r/G7BC650C86FEEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7BC650C86FEEN.html>